In situ thrombosis in pulmonary arterial aneurysms due to Behçet’s disease and efficacy of immunosuppressive therapy

Sevket Ozkaya1*, Unal Sahin1, Aziz Gumus1, Filiz Taşçı2, Halit Çınarka1 and Asiya Yavuz1

Abstract
Behçet Disease (BD) is a systemic vasculitis characterized by recurrent oral and genital ulcers and uveitis, arthritis, and involvement of the gastrointestinal tract, central nervous system and blood vessels. The aneurysms of the pulmonary arteries, with or without thrombosis, are typical manifestation of BD. We report a case with BD, pulmonary arterial aneurysms (PAA) and in situ thrombosis. We aimed to show the effectiveness of immunosuppressive treatment on in situ thrombosis in a case with PAA and BD.

Keywords: Behçet’s disease, Pulmonary artery aneurysm, In situ thrombosis, Immunosuppressive treatment

Background
Behçet’s disease (BD) was firstly described by Hulusi Behçet in 1937. It is a systemic vasculitis characterized by recurrent oral and genital ulcers and uveitis, arthritis, and involvement of the gastrointestinal tract, central nervous system and blood vessels [1]. Pulmonary artery aneurysm (PAA) is reported in 1.5% of adults with BD. Thrombosis of the pulmonary arteries in BD is usually an in situ thrombosis [2]. Some articles reported that immunosuppressive therapy is essential, and anticoagulant therapy might not be required for the treatment of venous disease associated with BD [3]. We aimed to show the effectiveness of immunosuppressive treatment on in situ thrombosis in a case with PAA and BD.

Case presentation
A 25-year-old, non-smoker, Turkish man was admitted to hospital with complaints of chest pain and cough. The chest radiography showed well-defined, rounded opacities on the left hemithorax (Figure 1). The thorax CT and MRI revealed vascular aneurysms with in situ thrombosis on the left pulmonary artery (Figure 2 and 3). The patient had history of recurrent oral and genital aphthous ulcers. The skin pathergy test was positive (Figure 4). BD was diagnosed based on these findings. The treatment was started with intravenous pulse methylprednisolone (250 mg per day for 3 days) and monthly 1,000 mg cyclophosphamide, and followed by 1 mg/kg per day of methylprednisolone orally, colchium and intravenous pulse of 1,000 mg cyclophosphamide-monthly. Thorax CT was repeated after 2 months of treatment. It showed that PAAs were reduced and in situ thrombosis in PAAs was completely resolved with immunosuppressive treatment (Figure 5). The approval of patient and of institution were taken to use their records for our study.

Conclusions
After the aorta, the pulmonary arteries are the most common site of arterial involvement among the pulmonary manifestations in patients with BD [4]. PAAs associated with BD tend to be multiple, as seen in our patient. The hemoptysis is the commonest symptom of PAA in BD, and one of the leading causes of death [5]. In the present case there was no hemoptysis. The aneurysms of the pulmonary arteries, with or without thrombosis, are typical manifestation of BD [6]. Tunac et al. reported mural thrombotic changes during regression of PAAs [7]. The underlying pathophysiologic process is inflammation of the vasa vasorum of the tunica media, which causes destruction of the elastic fibers of the...
media and dilatation of the vessel lumen. Thickening of the vessel wall is caused by inflammation and infiltration by lymphocytes, plasma cells and neutrophils. Thrombosis of the pulmonary arteries in BD is usually an in situ thrombosis [2,8]. Because the main problem is the inflammation of pulmonary arteries, the main stay of treatment should be the anti-inflammatory and immunosuppressive agents in patients with PAA and BD. A combination of cyclophosphamide and methylprednisolone is used most frequently in patients with PAA [9].

We know that anticoagulant therapy could increase the risk of aneurysmal rupture and anticoagulant drugs might be unnecessary in BD [5]. Mehta et al. reported a case with in situ thrombosis with BD [10]. They reported the patient had remained clinically stable with no further episodes of hemoptysis with immunosuppressive treatment including dexamethasone and cyclophosphamide [10]. However, there was no radiologically demonstrated efficacy of immunosuppressive treatment on in situ

Figure 1 Chest radiography is showing the well-shaped, round hilar opacities on left hemithorax.

Figure 2 Thorax CT scans are showing the aneurysmatic dilatations and in situ thrombosis in the left pulmonary artery (white arrows).
thrombosis. The aim of this report has been to demonstrate the effectiveness of immunosuppressive treatment on in situ thrombosis with PAA in a patient with BD. Contrast-enhanced thorax CT revealed the in situ thrombosis on the wall of PAA. After the immunosuppressive treatment the in situ thrombosis was completely resolved and PAA was reduced.

In conclusion, inflammation in pulmonary arteries is causing in situ thrombosis and it contributes to the development of PAA in patients with BD. The anti-inflammatory and immunosuppressive drugs are essential for the treatment of in situ thrombosis and PAA in patients with BD.

Consent
Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interest
The authors declare that they have no competing interests.

Authors’ contributions
SO, US, AG, FT, HC, AY have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data. All authors read and approved the final manuscript.

Author details
1Rize University, Faculty of Medicine, Department of Pulmonary Medicine, Rize, Turkey. 2Rize Education and Research Hospital, Department of Radiology, Rize, Turkey.

Received: 27 June 2012 Accepted: 6 October 2012 Published: 18 October 2012

References
1. Behçet H. Ü berrezidivierende, aphtöse, durchein virus verursachtes Geschwüre am Mund, Auge und an den genitalen. Dermatol Wochenschr 1937; 105:1152–1157.
2. Yılmaz S, Cimen KA: Pulmonary artery aneurysms in Behçet’s disease. Rheumatol Int 2010, 30:1401–1403.
3. Ahn JK, Lee YS, Jeon CH, Koh EM, Cha H-S: Treatment of venous thrombosis associated with Behçet’s disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008, 27:201–205.
4. Yoon YH, Kim KH, Baek WK, Kim JT, Shon KH, Kim YS, et al: Pulmonary artery pseudoaneurysm in a patient with Behçet disease. J Thorac Cardiovasc Surg 2004, 127:290–292.
5. Erkan F, Gül A, Tasalı E: Pulmonary manifestations of Behçet’s disease. Thorax 2001, 56:572–578.
6. Hiller N, Lieberman S, Chajek-Shaul T, Bar-Ziv J, Shaham D: Thoracic manifestations of Behçet Disease at CTI. Radiographics 2004, 24:801–808.
7. Tunaci M, Ozkorkmaz B, Tunaci A, et al: CT findings of pulmonary artery aneurysms during treatment for Behçet’s disease. Am J Roentgenol 1999, 172:729–733.
8. Raz I, Okon E, Chajek-Shaul T: Pulmonary manifestations in Behçet’s syndrome. Chest 1989, 95:585–589.
9. Fresko I, Yurdakul S, Hamuryudan V, et al: The management of Behçet’s syndrome. Ann Med Interne 1999, 150:576–581.
10. Mehta AA, Jose W, Balamugesh C: Right hilar mass with hemoptysis: An unusual presentation of uncommon disorder. Lung India 2011, 28(4):305–308.

Cite this article as: Ozkaya et al: In situ thrombosis in pulmonary arterial aneurysms due to Behçet’s disease and efficacy of immunosuppressive therapy. Multidisciplinary Respiratory Medicine 2012 7:33.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit